Cresset Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cresset Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,919	Closed	-$977K	–	1808
2024 Q3	$977K	Buy	2,919 +159	+6%	+$50.5K	﹤0.01%	1176
2024 Q2	$754K	Sell	2,760 -659	-19%	-$192K	﹤0.01%	1227
2024 Q1	$1.18M	Buy	3,419 +642	+23%	+$211K	0.01%	902
2023 Q4	$897K	Buy	2,777 +716	+35%	+$224K	0.01%	941
2023 Q3	$739K	Buy	2,061 +534	+35%	+$206K	﹤0.01%	988
2023 Q2	$579K	Buy	+1,527	New	+$621K	﹤0.01%	1203
2021 Q4	–	Sell	-591	Closed	-$440K	–	1139
2021 Q3	$440K	Buy	591 +91	+18%	+$68.2K	0.01%	684
2021 Q2	$323K	Buy	500 +40	+9%	+$24.3K	﹤0.01%	734
2021 Q1	$263K	Buy	460 +43	+10%	+$25.5K	﹤0.01%	738
2020 Q4	$243K	Buy	+417	New	+$237K	﹤0.01%	632
2019 Q2	–	Sell	-256	Closed	-$78K	–	616
2019 Q1	$78K	Buy	256 +66	+35%	+$17.8K	﹤0.01%	633
2018 Q4	$44K	Buy	+190	New	+$51K	﹤0.01%	513

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Cresset Asset Management's BIO Position: Q4 2024 in Review

Cresset Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 2,919 shares — an estimated $977K sold.

Cresset Asset Management first reported a position in BIO in Q4 2018 and held it in 12 quarters. The position peaked at $1.18M in Q1 2024. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Cresset Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
Cresset Asset Management sold 2,919 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $977K.
Cresset Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 12 quarters.
Cresset Asset Management's Bio-Rad Laboratories Class A position peaked at $1.18M in Q1 2024.
456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.